A new 2-in-1 antibiotic against high priority superbugs
Location: Czechia, Prague
Employees: 11-50
Founded date: 1996
Investors 1
| Date | Name | Website |
| - | TVM Capita... | tvm-lifesc... |
Mentions in press and media 2
| Date | Title | Description |
| 25.07.2016 | FDA grants QIDP and Fast Track Designations to MCB3837, Morphochem’s novel intravenous antibacterial to treat C. difficile infections | Munich (Germany), July 25, 2016 — Morphochem, a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as ... |
| 22.06.2016 | Morphochem’s Investigational New Drug (IND) application accepted by the FDA – Novel antibacterial for intravenous treatment of Clostridium difficile infections (CDI), MCB3837/MCB3681, can now move int... | Munich, Germany, June 22, 2016 — Morphochem, a private clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for the company’s nov... |